Effects of Beraprost with or without NOS Inhibitor on Aldosterone and Hemodynamics in Healthy Cats
Preprint
- 30 September 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Objectives: The aim of the study was to evaluate the effects of oral administration of clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess plasma aldosterone and renin concentrations, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance. Results: Beraprost reduced plasma aldosterone when compared to the placebo (P < 0.05); this was reversed when NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was added to beraprost treatment (P < 0.01). No differences in the plasma renin concentration or hemodynamic parameters were detected between beraprost and placebo. The correlation ratios (η2) showed opposite relationships between beraprost and added L-NAME effects on aldosterone concentration, mean blood pressure, heart rate, renal plasma flow, and renal vascular resistance (P < 0.001). Conclusions: In healthy cats, the clinical dose of beraprost suppresses plasma concentration of aldosterone, which can be reversed by inhibition of NOS.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteriesEuropean Journal of Pharmacology, 2017
- A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritisProstaglandins & Other Lipid Mediators, 2014
- Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease ratsEuropean Journal of Pharmacology, 2013
- Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigmsKidney International, 2012
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney diseaseKidney International, 2011
- Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trialJACC, 2002
- The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1997
- Short-term hemodynamic effect of a new oral PGI2 analogue, Beraprost, in primary and secondary pulmonary hypertensionThe American Journal of Cardiology, 1996
- Effects of inhibition of nitric oxide synthase on systemic arterial pressure and renal vascular resistance in catsResearch in Veterinary Science, 1993
- Haemodynamic changes and acetylcholine‐induced hypotensive responses after NG‐nitro‐l‐arginine methyl ester in rats and catsBritish Journal of Pharmacology, 1991